Sequent Scientific climbs over 7 per cent on receiving EU GMP approval for its tablets
Sequent Scientific Limited announced that it has got European Union good manufacturing practices (EU GMP) approval, which is considered as the highest recognition available by companies in the pharmaceutical space for its tablets dosage manufacturing line in Turkey.
In addition to this, the approval was further complemented by the successful renewal of EU GMP licence for eight other manufacturing lines of the company used for various dosage forms including beta-lactam, non-beta lactam, terminal sterilisation, mastitis, powder beta-lactam, aerosol, pesticide, and solids in Turkey.
With these approvals, Alivira, which is a 100 per cent-owned subsidiary of the company now has multiple EU GMP-approved facilities globally, allowing it to better serve the needs of its customers in the regulated markets of Europe. It will also help the company gain access to alternative manufacturing sites to ensure supply of high quality products.
At the close of the market on Thursday, the share price of the company was last seen trading at Rs 288, up by 7.54 per cent on BSE.
---